Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Approved by the Medicines and Healthcare products Regulatory Agency (MHRA), the injectable will cut down on immunotherapy ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier ...

The Interleukin-2 (IL-2) market is witnessing rapid growth due to advancements in cancer immunotherapy and autoimmune disease management. IL-2, a vital cytokine, promotes T-cell growth, with therapies ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the safety and efficacy of ...